"180-day Exclusivity – Should be ""Rolling"" III Branded companies still employ strategies designed to eliminate or diminish the ""reward"" for successful"
{"Image DocumentName": "180-day Exclusivity \u2013 Should be Rolling III", "Image ImageDescription": "Branded companies still employ strategies designed to eliminate or diminish the reward for successful First Filers, built into the Act, in the 180-day provision. Litigation over FDA actions affecting 180-day Marketing Exclusivity continues. See, e.g., Teva Pharmaceuticals, Inc. v. Kathleen Sebelius, et al., No (D.C.Cir., March 2, 2010); and Millenium Pharmaceuticals, Inc., et al. v. Teva Parental Medicines, Inc., et al., 2010 WL (D.Del., April 14, 2010).", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}